Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies

被引：0
|
作者：
Enrique Grande
Michael C. Kreissl
Sebastiano Filetti
Kate Newbold
Walter Reinisch
Caroline Robert
Martin Schlumberger
Lærke K. Tolstrup
Jose L. Zamorano
Jaume Capdevila
机构：
[1] Hospital Ramón y Cajal,Servicio de Oncología Médica
[2] University Hospital of Wuerzburg,Department of Nuclear Medicine
[3] Central Hospital of Augsburg,Department of Nuclear Medicine
[4] University of Rome “Sapienza”,Department of Internal Medicine and Medical Specialities
[5] Royal Marsden Hospital,Thyroid Unit
[6] Medical University of Vienna,Division of Gastroenterology and Hepatology, Department of Internal Medicine III
[7] University of Paris-Sud,Department of Medical Oncology, Dermatology Unit and INSERM U981, Gustave Roussy Institute
[8] University of Paris-Sud,Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute
[9] Odense University Hospital,Department of Oncology, Clinical Research Unit
[10] Hospital Ramón y Cajal,Cardiology Service
[11] Vall d’Hebron University Hospital,Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit
[12] Autonomous University of Barcelona,undefined
来源：
Advances in Therapy | 2013年 / 30卷
关键词：
Adverse effects; Antineoplastic agents/adverse effects; Cardiovascular; Dermatology; Medullary thyroid cancer; Medullary thyroid carcinoma; Patient safety; Piperidines/therapeutic use; Protein kinase inhibitors; Thyroid neoplasms/drug therapy; Vandetanib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：945 / 966
页数：21
相关论文
共 50 条
  • [41] Cabozantinib for progressive metastatic medullary thyroid cancer: a review
    Colombo, Joshua R.
    Wein, Richard O.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 395 - 404
  • [42] Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer
    Madhavi Nagilla
    Rebecca L. Brown
    Ezra E. W. Cohen
    Advances in Therapy, 2012, 29 : 925 - 934
  • [43] Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report
    Milner, Thomas D.
    Ronghe, Milind
    Shaikh, Mohamad G.
    MacGregor, Fiona B.
    Reed, Nicholas
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2019, 41 (05) : E329 - E332
  • [44] Medullary thyroid cancer: Medical management and follow-up
    Traugott A.
    Moley J.F.
    Current Treatment Options in Oncology, 2005, 6 (4) : 339 - 346
  • [45] Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer
    Sun, Yongkun
    Du, Feng
    Gao, Ming
    Ji, Qinghai
    Li, Zhendong
    Zhang, Yuan
    Guo, Zhuming
    Wang, Jun
    Chen, Xiangjin
    Wang, Jinwan
    Chi, Yihebali
    Tang, Pingzhang
    THYROID, 2018, 28 (11) : 1455 - 1461
  • [46] Novel Therapeutics and Treatment Strategies for Medullary Thyroid Cancer
    Walgama, Evan
    Busaidy, Naifa
    Zafereo, Mark
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2022, 51 (02) : 379 - 389
  • [47] Surgical management of sporadic medullary thyroid cancer
    Noullet, S.
    Tresallet, C.
    Godiris-Petit, G.
    Hoang, C.
    Leenhardt, L.
    Menegaux, F.
    JOURNAL OF VISCERAL SURGERY, 2011, 148 (04) : E244 - E249
  • [48] Initial surgical management of medullary thyroid cancer
    Coan, Kathryn E.
    Wang, Tracy S.
    INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY, 2016, 3 (03) : 259 - 266
  • [49] Medical Management of Metastatic Medullary Thyroid Cancer
    Maxwell, Jessica E.
    Sherman, Scott K.
    O'Dorisio, Thomas M.
    Howe, James R.
    CANCER, 2014, 120 (21) : 3287 - 3301
  • [50] Advances in the management of hereditary medullary thyroid cancer
    Machens, A
    Ukkat, J
    Brauckhoff, M
    Gimm, O
    Dralle, H
    JOURNAL OF INTERNAL MEDICINE, 2005, 257 (01) : 50 - 59
12345